These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17974748)

  • 1. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art.
    Arnold LE; Lindsay RL; López FA; Jacob SE; Biederman J; Findling RL; Ramadan Y
    Pediatrics; 2007 Nov; 120(5):1100-6. PubMed ID: 17974748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adderall XR: long acting stimulant for single daily dosing.
    Sallee FR; Smirnoff AV
    Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action.
    Steinhoff KW
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S99-106. PubMed ID: 15352536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.
    Ashkenasi A
    Pediatr Neurol; 2011 Dec; 45(6):381-6. PubMed ID: 22115000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
    Warshaw EM; Paller AS; Fowler JF; Zirwas MJ
    Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
    Elia J; Wilson Z; La Porta LS; Algon SA; Prowler ML; Cartwright ST; McKenna PA; Laracy S; Takeda T; Borgmann-Winter K
    Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
    McGough JJ; Pataki CS; Suddath R
    Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
    González MA; Campbell D; Rubin J
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
    Cox DJ; Mikami AY; Cox BS; Coleman MT; Mahmood A; Sood A; Moore M; Burket R; Merkel RL
    Arch Pediatr Adolesc Med; 2008 Aug; 162(8):793-4. PubMed ID: 18678816
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in psychotropic formulations.
    Keith S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):996-1008. PubMed ID: 16678954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention deficit/hyperactivity disorder: complexities and controversies.
    Schonwald A; Lechner E
    Curr Opin Pediatr; 2006 Apr; 18(2):189-95. PubMed ID: 16601502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulant medication and short attention span: a clinical approach.
    Davy T; Rodgers CL
    J Dev Behav Pediatr; 1989 Dec; 10(6):313-8. PubMed ID: 2513337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.
    Capp PK; Pearl PL; Conlon C
    Expert Rev Neurother; 2005 May; 5(3):325-31. PubMed ID: 15938665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.